Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

By Xiaowei Xu, Xiao-Xin Wu, Xiangmei Jiang, Kai-jin Xu, L. Ying, Chunlian Ma, Shi-bo Li, Huaying Wang, Sheng Zhang, Hai-Nv Gao and 4 more. British medical journal, 2020

1,961 citations recorded by the source corpus.

Abstract Objective To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019). Design Retrospective case series. Setting Seven hospitals in Zhejiang province, China. Participants 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection. Data were collected from 10 January 2020 to 26 January 2020. Main outcome measures Clinical data, collected using a standardised case report form, such as temperature, history of exposure, incubation period. If information was not clear, the working group in Hangzhou contacted the doctor responsible for treating the patient for clarification. Results Of the 62 patients studied (median age 41 years), only one was admitted to an intensive care unit, and no patients died during the study. According to research, none of the infected patients in Zhejiang province were ever exposed to the Huanan seafood market, the original source of the virus; all studied cases were infected by human to human transmission. The most common symptoms at onset of illness were fever in 48 (77%) patients, cough in 50 (81%), expectoration in 35 (56%), headache in 21 (34%), myalgia or fatigue in 32 (52%), diarrhoea in 3 (8%), and haemoptysis in 2 (3%). Only two patients (3%) developed shortness of breath on admission. The median time from exposure to onset of illness was 4 days (interquartile range 3-5 days), and from onset of symptoms to first hospital admission was 2 (1-4) days. Conclusion As of early February 2020, compared with patients initially infected with SARS-Cov-2 in Wuhan, the symptoms of patients in Zhejiang province are relatively mild.

Subfields: Infectious Diseases, Neurology

View Paper: https://www.semanticscholar.org/paper/7cd893749d384d4f55bdf43fbcedcd30b3bc0041

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

In Neurology

Citations in the corpus

Acute respiratory failure in COVID-19: is it “typical” ARDS? (2020, background): “Although several studies have reported the clinical features of COVID-19 [1, [8] [9] [10] [11] [12] [13] , our understanding about it remains limited [14] .”
Biomarkers associated with COVID-19 disease progression (2020, background): “There appears to be geographic variability in the percentage of patients with lymphopenia as shown in a retrospective study [107].”
Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study (2020, background): “[5] [6] [7] [8] [9] Neurological manifestations such as con fusion are infrequently reported in patients with COVID-19 (9·1%) but are almost absent in patients with SARS. 8 Another apparent difference between SARS-CoV-2 and SARS-CoV is the speed at which the COVID-19 outbreak is expanding.”
Rapid implementation of mobile technology for real-time epidemiology of COVID-19 (2020, background): “Further, symptoms of COVID-19 vary widely, with fever and dry cough reportedly the most prevalent, though numerous investigations have demonstrated that asymptomatic carriage is a significant determinant of community spread (5) (6) (7) (10) (11) (12) (13) .”
Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients (2020, neutral): “[12] [13] The reason may be that our hospital is the severe treatment base in Hainan Province, which has caused a significant increase in the proportion of severe illness in our hospital and caused an increase in the mortality rate of young people.”
Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis (2020, background): “Six studies, including 324 severe group cases and 1234 non-severe group cases, provided the data in terms of hypertension, diabetes, and COPD [1, [4] [5] [6] [7] [8] .”
Estimates of the severity of coronavirus disease 2019: a model-based analysis (2020, neutral): “These criteria typically included a combination of symptoms (eg, cough and fever) combined with recent travel history to the affected region (Wuhan, or Hubei province) 2,17 .”